The quadrivalent approach to influenza vaccination

Journal of Infectious Diseases

Volumn 208, Issue 4, 2013, Pages 539-540

  Dolin, Raphael ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Inactivated influenza vaccine; Influenza; Influenza B; Influenza vaccine; Live attenuated influenza vaccine; Quadrivalent influenza vaccine

Indexed keywords

INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; QUADRIVALENT INACTIVATED VACCINE; UNCLASSIFIED DRUG;

DRUG EFFICACY; DRUG SAFETY; HEALTH CARE COST; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION PREVENTION; INFLUENZA A; INFLUENZA B; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INJECTION SITE PAIN; NONHUMAN; NOTE; PRIORITY JOURNAL; SEASONAL INFLUENZA; TREATMENT PLANNING; VIRUS STRAIN;

INACTIVATED INFLUENZA VACCINE; INFLUENZA; INFLUENZA B; INFLUENZA VACCINE; LIVE ATTENUATED INFLUENZA VACCINE; QUADRIVALENT INFLUENZA VACCINE;

FEMALE; HUMANS; INFLUENZA VACCINES; MALE;

EID: 84880942873     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit264     Document Type: Note

References (13)

1. Influenza-associated pediatric deaths- United States, September 2010-August 2011. MMWR Morb Mortal Wkly Rep 2011; 60:1233-8.
2. Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010; 59:1-62.
3. Esposito S, Cantarutti L, Molteni CG, et al. Clinical manifestations and socio-economic impact of influenza among healthy children in community. J Infect 2011; 62: 379-87.
4. Langley JM, Martinez AC, Chatterjee A, et al. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children. J Infect Dis 2013; 208:544-53.
5. Domachowske JB, Pankow-Culot H, Bautista M, et al. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years. J Infect Dis 2013; 207:1878-87.
6. Greenberg DP, Robertson CA, Noss MJ, et al. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine 2013; 31:770-6.
7. Beran JI, Peeters M, Dewé W, et al. Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults. BMC Infect Dis 2013; 13:224.
8. Block SL, Yi T, Sheldon E, et al. A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults. Vaccine 2011; 29:9391-7.
9. Block SL, Falloon J, Hirschfield JA, et al. Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children. Pediatr Infect Dis J 2012; 31:745-51.
10. Toback SL, Levin MJ, Block SL, et al. Quadrivalent Ann Arbor strain live-attenuated influenza vaccine. Expert Rev Vaccines 2012; 11:1293-303.
11. Reed C, Meltzer MI, Finelli L, Fiore A. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine 2012; 30:1993-8.
12. Lee BY, Bartsch SM, Willig AM. The economic value of a quadrivalent versus trivalent influenza vaccine. Vaccine 2012; 30: 7443-6.
13. Prevention and control of influenza with vaccines: interim recommendations of the Advisory Committee on Immunization Practices (ACIP) CDC. MMWR Morb Mortal Wkly Rep 2013; 62:356-6.